<DOC>
	<DOCNO>NCT00648037</DOCNO>
	<brief_summary>The purpose study determine prevent Epstein Barr Virus lymphomas monthly administration ( antibody ) protein B lymphocytes call Rituximab . Although medicine approve Food Drug Administration treat patient type lymphoma , use treat small number patient EBV lymphomas type B-cell leukemia , approve try prevent EBV-lymphomas . Use Rituximab try prevent EBV-lymphomas therefore experimental .</brief_summary>
	<brief_title>Rituximab ( Rituxan ) Prevention EBV-LPD Epstein Barr Virus ( EBV ) Lymphoproliferative Disorder Post T Cell Depleted Unrelated HLA Mis-matched Related HSCT</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient must recipient aT cell deplete unrelated HLA mismatch related HSCT treatment malignancy immunodeficiency disease . Patients must ANC &gt; = 1500 cells/ul day first treatment . Patients acute chronic leukemia , MDS prior transplant must remission define &lt; 5 % blast bone marrow . Patient must remission . Patient must Hepatitis B surface antigen negative pre transplant . Patients must adequate cardiac function define leave ventricular ejection fraction rest &gt; 50 % document pretransplant . Patient may either gender ethnic background . Patient may age . There upper age restriction . Patients guardian must able understand nature risk propose study able sign consent . Karnofsky score &lt; 70 % Female patient pregnant lactate . Evidence EBVLPD circulate EBV copy number &gt; 1000 . Active uncontrolled bacterial fungal infection . Prior history Hepatitis B infection Hepatitis B surface antigen positivity pre transplant . HIV1,2 seropositive patient . Patients guardian sign informed consent . Patients prior allergic reaction Rituximab murine monoclonal antibody . Patients take investigational agent another protocol unless discuss approve advance Genentech IDEC Therapeutic Director .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>RITUXIMAB</keyword>
	<keyword>Lymphoma</keyword>
</DOC>